Literature DB >> 11481447

A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist.

W Xu1, S R Presnell, J Parrish-Novak, W Kindsvogel, S Jaspers, Z Chen, S R Dillon, Z Gao, T Gilbert, K Madden, S Schlutsmeyer, L Yao, T E Whitmore, Y Chandrasekher, F J Grant, M Maurer, L Jelinek, H Storey, T Brender, A Hammond, S Topouzis, C H Clegg, D C Foster.   

Abstract

IL-22 is an IL-10 homologue that binds to and signals through the class II cytokine receptor heterodimer IL-22RA1/CRF2-4. IL-22 is produced by T cells and induces the production of acute-phase reactants in vitro and in vivo, suggesting its involvement in inflammation. Here we report the identification of a class II cytokine receptor designated IL-22RA2 (IL-22 receptor-alpha 2) that appears to be a naturally expressed soluble receptor. IL-22RA2 shares amino acid sequence homology with IL-22RA1 (also known as IL-22R, zcytor11, and CRF2-9) and is physically adjacent to IL-20Ralpha and IFN-gammaR1 on chromosome 6q23.3-24.2. We demonstrate that IL-22RA2 binds specifically to IL-22 and neutralizes IL-22-induced proliferation of BaF3 cells expressing IL-22 receptor subunits. IL-22RA2 mRNA is highly expressed in placenta and spleen by Northern blotting. PCR analysis using RNA from various tissues and cell lines showed that IL-22RA2 was expressed in a range of tissues, including those in the digestive, female reproductive, and immune systems. In situ hybridization revealed the dominant cell types expressing IL-22RA2 were mononuclear cells and epithelium. Because IL-22 induces the expression of acute phase reactants, IL-22RA2 may play an important role as an IL-22 antagonist in the regulation of inflammatory responses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11481447      PMCID: PMC55483          DOI: 10.1073/pnas.171303198

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta ) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes.

Authors:  S V Kotenko; L S Izotova; O V Mirochnitchenko; E Esterova; H Dickensheets; R P Donnelly; S Pestka
Journal:  J Biol Chem       Date:  2000-10-16       Impact factor: 5.157

2.  Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9.

Authors:  L Dumoutier; J Louahed; J C Renauld
Journal:  J Immunol       Date:  2000-02-15       Impact factor: 5.422

3.  Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R.

Authors:  M H Xie; S Aggarwal; W H Ho; J Foster; Z Zhang; J Stinson; W I Wood; A D Goddard; A L Gurney
Journal:  J Biol Chem       Date:  2000-10-06       Impact factor: 5.157

Review 4.  Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes.

Authors:  S V Kotenko; S Pestka
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

5.  Interleukin 20: discovery, receptor identification, and role in epidermal function.

Authors:  H Blumberg; D Conklin; W F Xu; A Grossmann; T Brender; S Carollo; M Eagan; D Foster; B A Haldeman; A Hammond; H Haugen; L Jelinek; J D Kelly; K Madden; M F Maurer; J Parrish-Novak; D Prunkard; S Sexson; C Sprecher; K Waggie; J West; T E Whitmore; L Yao; M K Kuechle; B A Dale; Y A Chandrasekher
Journal:  Cell       Date:  2001-01-12       Impact factor: 41.582

6.  A new method for predicting signal sequence cleavage sites.

Authors:  G von Heijne
Journal:  Nucleic Acids Res       Date:  1986-06-11       Impact factor: 16.971

7.  Identification of common molecular subsequences.

Authors:  T F Smith; M S Waterman
Journal:  J Mol Biol       Date:  1981-03-25       Impact factor: 5.469

8.  Human interleukin-10-related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor.

Authors:  L Dumoutier; E Van Roost; D Colau; J C Renauld
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

9.  Transient neonatal diabetes mellitus in a child with invdup(6)(q22q23) of paternal origin.

Authors:  E I Arthur; J Zlotogora; I Lerer; J Dagan; K Marks; D Abeliovich
Journal:  Eur J Hum Genet       Date:  1997 Nov-Dec       Impact factor: 4.246

10.  Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo.

Authors:  R Palacios; M Steinmetz
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

View more
  70 in total

Review 1.  Structure and function of interleukin-22 and other members of the interleukin-10 family.

Authors:  Daniela Barretto Barbosa Trivella; José Ribamar Ferreira-Júnior; Laure Dumoutier; Jean-Christophe Renauld; Igor Polikarpov
Journal:  Cell Mol Life Sci       Date:  2010-05-08       Impact factor: 9.261

2.  Structure of IL-22 bound to its high-affinity IL-22R1 chain.

Authors:  Brandi C Jones; Naomi J Logsdon; Mark R Walter
Journal:  Structure       Date:  2008-07-03       Impact factor: 5.006

3.  IL-22 is involved in liver regeneration after hepatectomy.

Authors:  Xiaodan Ren; Bin Hu; Lisa M Colletti
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-10-29       Impact factor: 4.052

4.  A polymorphism of interleukin-22 receptor alpha-1 is associated with the development of childhood IgA nephropathy.

Authors:  Jin-Soon Suh; Seong H Cho; Joo-Ho Chung; Ahrim Moon; Yong-Koo Park; Byoung-Soo Cho
Journal:  J Interferon Cytokine Res       Date:  2013-05-09       Impact factor: 2.607

Review 5.  IL-20 receptor cytokines in autoimmune diseases.

Authors:  Jun Chen; Rachel R Caspi; Wai Po Chong
Journal:  J Leukoc Biol       Date:  2018-09-07       Impact factor: 4.962

Review 6.  Interleukin-22: a likely target for treatment of autoimmune diseases.

Authors:  Xuyan Yang; Song Guo Zheng
Journal:  Autoimmun Rev       Date:  2014-01-10       Impact factor: 9.754

Review 7.  Targeting interleukins for the treatment of inflammatory bowel disease-what lies beyond anti-TNF therapy?

Authors:  Mairi H McLean; Markus F Neurath; Scott K Durum
Journal:  Inflamm Bowel Dis       Date:  2014-02       Impact factor: 5.325

Review 8.  IL-22 in tissue-protective therapy.

Authors:  Heiko Mühl; Patrick Scheiermann; Malte Bachmann; Lorena Härdle; Anika Heinrichs; Josef Pfeilschifter
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

9.  Association between CXCR2 and IL-22BP expression indicate a poor outcome for gastric adenocarcinoma progression.

Authors:  Shi Bin Yang; Fanghai Han; Jian Hai Wu; Zhi Zhao; Wenhua Zhan
Journal:  Oncol Lett       Date:  2016-06-28       Impact factor: 2.967

10.  IL-22BP is produced by eosinophils in human gut and blocks IL-22 protective actions during colitis.

Authors:  J C Martin; G Bériou; M Heslan; C Bossard; A Jarry; A Abidi; P Hulin; S Ménoret; R Thinard; I Anegon; C Jacqueline; B Lardeux; F Halary; J-C Renauld; A Bourreille; R Josien
Journal:  Mucosal Immunol       Date:  2015-09-02       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.